Related Experiment Videos

On indications for treatment of the hyperphenylalaninemic neonate

Insights

Newborn screening identified infants with high phenylalanine levels. Dietary management is initiated for elevated levels, but phenylalanine tolerance tests distinguish phenylketonuria (PKU) from persistent hyperphenylalaninemia (HPA).

Area of Science:

  • Biochemistry
  • Neonatal screening
  • Metabolic disorders

Background:

  • Newborn screening programs aim to detect metabolic disorders early.
  • Phenylketonuria (PKU) and persistent hyperphenylalaninemia (HPA) are conditions characterized by elevated phenylalanine levels.

Purpose of the Study:

  • To evaluate the effectiveness of initial screening tests in differentiating PKU from HPA.
  • To identify reliable methods for distinguishing between PKU and HPA in neonates.

Main Methods:

  • Analysis of Guthrie screening test values in a large cohort of neonates.
  • Confirmatory testing for infants with elevated phenylalanine levels.
  • Assessment of dietary phenylalanine tolerance and 24-hour phenylalanine load tests.

Main Results:

  • Out of 488,006 neonates, 58 had phenylalanine values above 2.5 mg/100 ml.
  • Eighteen infants were diagnosed with PKU and fourteen with HPA.
  • Initial and confirmatory tests could not differentiate between PKU and HPA.

Conclusions:

  • A phenylalanine-restricted diet is initiated for infants with serum phenylalanine > 10 mg/100 ml.
  • Dietary tolerance and phenylalanine load tests are crucial for differentiating PKU from HPA.

Related Concept Videos